Equities analysts expect Collegium Pharmaceutical (NASDAQ:COLL) to announce earnings of ($0.69) per share for the current quarter, Zacks reports. Four analysts have provided estimates for Collegium Pharmaceutical’s earnings. The highest EPS estimate is ($0.23) and the lowest is ($1.01). Collegium Pharmaceutical posted earnings of ($0.79) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 12.7%. The business is scheduled to announce its next quarterly earnings report on Wednesday, May 9th.
On average, analysts expect that Collegium Pharmaceutical will report full-year earnings of ($0.76) per share for the current fiscal year, with EPS estimates ranging from ($1.39) to ($0.40). For the next fiscal year, analysts forecast that the business will report earnings of $1.00 per share, with EPS estimates ranging from ($0.16) to $1.98. Zacks’ earnings per share calculations are a mean average based on a survey of research analysts that cover Collegium Pharmaceutical.
Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings results on Wednesday, March 7th. The specialty pharmaceutical company reported ($0.54) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.02. The business had revenue of $10.79 million for the quarter, compared to analyst estimates of $9.88 million. Collegium Pharmaceutical had a negative net margin of 262.91% and a negative return on equity of 73.00%. The company’s revenue for the quarter was up 728.4% on a year-over-year basis.
Shares of COLL traded down $0.02 during trading hours on Monday, reaching $21.79. 564,862 shares of the company traded hands, compared to its average volume of 610,344. The firm has a market capitalization of $719.60, a price-to-earnings ratio of -8.82 and a beta of 0.76. Collegium Pharmaceutical has a 12 month low of $7.37 and a 12 month high of $29.90.
In related news, Chairman Michael Thomas Heffernan sold 20,000 shares of Collegium Pharmaceutical stock in a transaction dated Tuesday, January 23rd. The shares were sold at an average price of $25.01, for a total transaction of $500,200.00. Following the completion of the transaction, the chairman now directly owns 535,395 shares of the company’s stock, valued at approximately $13,390,228.95. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Alison B. Fleming sold 6,928 shares of Collegium Pharmaceutical stock in a transaction dated Wednesday, January 10th. The shares were sold at an average price of $19.07, for a total transaction of $132,116.96. Following the transaction, the insider now directly owns 32,651 shares of the company’s stock, valued at $622,654.57. The disclosure for this sale can be found here. Over the last three months, insiders have sold 46,928 shares of company stock valued at $1,082,317. 25.76% of the stock is currently owned by corporate insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of COLL. Benjamin F. Edwards & Company Inc. lifted its position in Collegium Pharmaceutical by 87.5% during the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 7,500 shares of the specialty pharmaceutical company’s stock valued at $138,000 after acquiring an additional 3,500 shares during the period. Acadian Asset Management LLC purchased a new position in Collegium Pharmaceutical in the fourth quarter worth about $176,000. JPMorgan Chase & Co. purchased a new position in Collegium Pharmaceutical in the third quarter worth about $192,000. Monarch Partners Asset Management LLC purchased a new position in Collegium Pharmaceutical in the fourth quarter worth about $264,000. Finally, Manchester Capital Management LLC purchased a new position in Collegium Pharmaceutical in the fourth quarter worth about $348,000. 86.39% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION WARNING: “-$0.69 EPS Expected for Collegium Pharmaceutical (COLL) This Quarter” was posted by Ticker Report and is owned by of Ticker Report. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright & trademark legislation. The correct version of this report can be read at https://www.tickerreport.com/banking-finance/3344013/0-69-eps-expected-for-collegium-pharmaceutical-coll-this-quarter.html.
About Collegium Pharmaceutical
Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and tampering, including chewing, crushing, and/or dissolving.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.